KR102863894B1 - Gpr35 조절제 - Google Patents

Gpr35 조절제

Info

Publication number
KR102863894B1
KR102863894B1 KR1020217026911A KR20217026911A KR102863894B1 KR 102863894 B1 KR102863894 B1 KR 102863894B1 KR 1020217026911 A KR1020217026911 A KR 1020217026911A KR 20217026911 A KR20217026911 A KR 20217026911A KR 102863894 B1 KR102863894 B1 KR 102863894B1
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217026911A
Other languages
English (en)
Korean (ko)
Other versions
KR20210119485A (ko
Inventor
로버트 히구치
Original Assignee
프로메테우스 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 바이오사이언시즈, 인크. filed Critical 프로메테우스 바이오사이언시즈, 인크.
Publication of KR20210119485A publication Critical patent/KR20210119485A/ko
Application granted granted Critical
Publication of KR102863894B1 publication Critical patent/KR102863894B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217026911A 2019-01-24 2020-01-23 Gpr35 조절제 Active KR102863894B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (2)

Publication Number Publication Date
KR20210119485A KR20210119485A (ko) 2021-10-05
KR102863894B1 true KR102863894B1 (ko) 2025-09-23

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026911A Active KR102863894B1 (ko) 2019-01-24 2020-01-23 Gpr35 조절제

Country Status (13)

Country Link
US (2) US11053251B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914256B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588077B2 (cg-RX-API-DMAC7.html)
KR (1) KR102863894B1 (cg-RX-API-DMAC7.html)
CN (1) CN113631168B (cg-RX-API-DMAC7.html)
AU (1) AU2020210930B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014566A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127786A1 (cg-RX-API-DMAC7.html)
IL (1) IL285074B2 (cg-RX-API-DMAC7.html)
MA (1) MA54825A (cg-RX-API-DMAC7.html)
MX (1) MX2021008941A (cg-RX-API-DMAC7.html)
TW (1) TWI845600B (cg-RX-API-DMAC7.html)
WO (1) WO2020154492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
AR123034A1 (es) * 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
CA3168304A1 (en) 2014-06-29 2016-01-07 Profile Products L.L.C. Bark and wood fiber growing medium
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
JP2022519819A (ja) 2019-02-08 2022-03-25 シーダーズ―シナイ メディカル センター Il18r1を標的とする炎症性疾患を処置するための方法、システム、およびキット
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
AR123034A1 (es) 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
IL302791A (en) 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4263585A4 (en) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmacology and Experimental Therpeutics, 2012, Vol. 343, pp. 683-695.

Also Published As

Publication number Publication date
EP3914256B1 (en) 2024-05-29
US20200239476A1 (en) 2020-07-30
US11773101B2 (en) 2023-10-03
MX2021008941A (es) 2021-10-13
IL285074A (en) 2021-09-30
CN113631168A (zh) 2021-11-09
EP3914256A1 (en) 2021-12-01
US20210380590A1 (en) 2021-12-09
US11053251B2 (en) 2021-07-06
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
IL285074B1 (en) 2024-08-01
AU2020210930A1 (en) 2021-09-09
CA3127786A1 (en) 2020-07-30
WO2020154492A1 (en) 2020-07-30
JP7588077B2 (ja) 2024-11-21
CN113631168B (zh) 2024-11-19
EP3914256A4 (en) 2022-09-28
JP2022518523A (ja) 2022-03-15
MA54825A (fr) 2021-12-01
AU2020210930B2 (en) 2025-08-14
IL285074B2 (en) 2024-12-01
KR20210119485A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
US11884680B2 (en) Bromodomain inhibitors
EP3914256B1 (en) Gpr35 modulators
EP3027616B1 (en) Azaindole compounds as modulators of rorc
JP5806417B2 (ja) Mgat2阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン
EA028814B1 (ru) АМИДЗАМЕЩЕННЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
AU2022253683A1 (en) Deuterated dhodh inhibitors
TW202332436A (zh) 治療用化合物
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
JP2022549435A (ja) Jak阻害剤
US20230151017A1 (en) Therapeutic agents targeting gpr35
EA048936B1 (ru) Модуляторы gpr35
WO2025064325A1 (en) Gpr35 modulators
HK40059523A (en) Gpr35 modulators
HK40097518A (en) Deuterated dhodh inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)